In particular, PD-L1hi EBV+ HL and DLBCL tumor cells may be suitable therapeutic targets for anti-PD-1/PD-L1 immunotherapy with the aim to unleash host antitumor immune responses. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.